Showing posts with label Concurrent Nimotuzumab in Chemoradiation of Advanced Inoperable Head and Neck Cancer. Show all posts
Showing posts with label Concurrent Nimotuzumab in Chemoradiation of Advanced Inoperable Head and Neck Cancer. Show all posts

Concurrent Nimotuzumab in Chemoradiation of Advanced Inoperable Head & Neck Cancer


Click here to view Slideshow

Introduction 





-Radiation therapy is the primary modality of treatment for loco-regionally advanced inoperable Head & Neck cancers
With Radiation therapy alone the rate of treatment failure is high, the overall cure rate and length of patient survival is lower. 

-New strategies have been continuously implemented : 
Use of concurrent chemotherapeutic drugs as radiation sensitizers has perhaps had the strongest impact on radiation therapy practice.

-Currently Biological response modifiers which enhance radiation and chemotherapy responses have been shown to further improve the therapeutic outcome of radiation therapy with acceptable morbidity.